Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone

Description

A prospective, single-site, double-arm, parallel, interventional, randomized, controlled clinical trial to assess 90-day rate of joint infections in subjects undergoing primary hip replacements after administration of Next Science No-Rinse Solution (hereby referred to as NS) vs SOC (saline irrigation). The Next Science treatment arm will exhibit greater reduction in rate of 90-day post-operative joint infection than SOC (saline) arm

Conditions

Joint Infection

Talk to us

Study Overview

On this page

Study Details

Study overview

A prospective, single-site, double-arm, parallel, interventional, randomized, controlled clinical trial to assess 90-day rate of joint infections in subjects undergoing primary hip replacements after administration of Next Science No-Rinse Solution (hereby referred to as NS) vs SOC (saline irrigation). The Next Science treatment arm will exhibit greater reduction in rate of 90-day post-operative joint infection than SOC (saline) arm

Clinical Evaluation of the Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone

Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone

Condition
Joint Infection
Intervention / Treatment

-

Contacts and Locations

Manhasset

North Shore University Hospital, Manhasset, New York, United States, 11030

New Hyde Park

Long Island Jewish Medical Center, New Hyde Park, New York, United States, 11040

New York

Lenox Hill Hospital, New York, New York, United States, 10075

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Adult that meets at least one of the below criteria at time of screening:
  • * American Society of Anesthesiologists (ASA) 3 2
  • * BMI \>35
  • * Patient with functional limitations as a result of disease1:
  • * Poorly treated hypertension
  • * Poorly treated diabetes
  • * Chronic renal failure
  • * Bronchospastic disease
  • * Disease with intermittent exacerbations
  • * Stable angina
  • * Implanted pacemaker
  • * Known history as an active nicotine use (smoker)
  • * Known history of uncontrolled diabetes mellitus (HgbA1C \> 7.0)
  • * Known history of end stage organ disease
  • * Known history of inflammatory arthritis and currently on rheumatological medication (DMARDs)
  • * Known history of current active cancer treatment (chemotherapy)
  • * Venous Disease (Surgical Risk Calculator from ACS-NSQIP)
  • * Charleston Comorbidity Score \> 2
  • * Elixhauser Score \>11
  • * Age 65 or older
  • 2. Subject is scheduled to primary joint replacement.
  • 3. Subject is willing and able to comply with all study procedures including transportation to the study site for all scheduled visits and be available for the duration of the study.
  • 4. Subject has understood, signed, and dated the informed consent form.
  • 1. Unable to provide signed and dated informed consent.
  • 2. Unable or unwilling to comply with all study-related procedures.
  • 3. Known history of allergic reaction to any of the study products or its components, including any products used for standard of care (such as dressings or any coverings)
  • 4. Subject has contraindications to general anesthesia
  • 5. Any subject positive for Covid-19 virus at time of surgical screening
  • 6. Subjects have evidence of prolonged QT segment, per EKG.
  • 7. Subjects from a vulnerable population, in accordance with 45 CFR 46 Subparts B, C, and D

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Northwell Health,

Giles Scuderi, PRINCIPAL_INVESTIGATOR, Northwell Health

Study Record Dates

2025-03-31